Objective-Nicotinic acetylcholine receptors, especially ␣7 (nAChR␣7), form Ca 2ϩ channels and are expressed on a variety of neuronal and nonneuronal cells. Also, megakaryocytic cells have been shown to contain components of a nonneuronal cholinergic system, including acetylcholine and acetylcholine esterase. However, the corresponding nAChRs and their role in platelet function have not been demonstrated until now. Our previous platelet transcriptome data indicated the presence of nAChR gene transcripts. Methods and Results-Here, we present evidence that human platelets and megakaryocytic precursor cells express nAChR␣7 subunits, as revealed by mRNA and protein expression. The subunits form functional Ca 2ϩ channels, as demonstrated by Ca 2ϩ entry in platelets induced by the nAChR␣7-selective agonist PNU-282987. PNU-282987 also enhanced fibrinogen receptor activation induced by classical platelet agonists (the thromboxane A 2 analog U46619 and ADP). Furthermore, agonist-induced platelet aggregation was significantly inhibited by the nAChR␣7-selective antagonists ␣-bungarotoxin and methyllycaconitine.
N icotinic acetylcholine receptors (nAChRs) are ligandgated pentameric ion channels that have been extensively studied in the central nervous system and at the neuromuscular junction. Recent studies demonstrated a widespread expression of the cholinergic system on nonneuronal cells. 1, 2 In humans, 12 neuronal subunits have been identified (␣2 to ␣10 and ␤2 to ␤4). Homopentameric channels formed by ␣7 subunits (nAChR␣7) exhibit the highest measured Ca 2ϩ permeability within the nAChR family and are sensitive to ␣-bungarotoxin (␣BGT). 3 The nAChR␣7 is expressed on a variety of tegumental cells, including keratinocytes, 4 endothelial cells, 5 and circulating blood cells (monocytes, macrophages, eosinophils, and lymphocytes 6 -10 ). Nicotine, a major constituent of cigarette smoke and also a selective cholinergic agonist, promotes directed migration and angiogenesis and is involved in the suppression of immune function, eg, by the cholinergic antiinflammatory pathway. 4 -7,11 Moreover, nicotine stimulates interaction between endothelial cells and monocytes and thereby facilitates arteriogenesis. 12 These effects are mainly mediated by Ca 2ϩ influx through the nAChR␣7 channel. Furthermore, the results of recent reports are indicative of a protective role of nicotine in platelet activation. 13, 14 In this context, it is proposed that nicotine acts as a potent antagonist because the sustained presence of nicotine in smokers leads to desensitization and closing of nAChRs. 2 Although, platelets express an impressive number of neuronal receptors and transporters, [15] [16] [17] [18] [19] the respective nAChRs were not yet identified. It has been suggested that platelets contain components of a nonneuronal cholinergic system, including acetylcholine (ACh), choline acetyltransferase, and acetylcholinesterase. 1, 20, 21 Cholinergic signaling during the development of platelets was proposed by several groups. [21] [22] [23] In previous microarray-based platelet RNA profiling studies, we found positive RNA signals for various nAChR subunits, especially ␣7. 24, 25 These findings encouraged us to investigate platelets and cells of the megakaryocytic lineage for the expression of nAChR␣7 subunits and its possible involvement in platelet function.
function for the last 10 days. Platelet-rich plasma (PRP) was obtained by centrifugation of citrated blood for RNA and protein experiments and centrifugation of acid citrate dextrose-coagulated blood for Ca 2ϩ measurements at 200g for 15 minutes. For platelet aggregometry and flow cytometry, blood was anticoagulated with hirudin.
Cholinergic Agonists and Antagonists
In our functional studies, we focused on the use of nAChR␣7-selective agonists and antagonists in selective concentrations. PNU-282987 (PNU; Tocris Bioscience, Ellisville, Mich) is a highly selective agonist for nAChR␣7 26 and was used at different concentrations as indicated. In addition, we used ACh or the stable analog carbamylcholine (CCh) because it represents the physiological agonist for cholinergic receptors (both purchased from Sigma-Aldrich, Taufkirchen, Germany). Nicotine (Sigma-Aldrich), selective for nAChR, was used in competition experiments. However, we abstained from the use of nicotine in functional studies because its function, especially in whole blood, is diverse, having both agonistic and antagonistic properties. The structurally unrelated competitive antagonists ␣BGT (a peptide) and methyllycaconitine (MLA, an alkaloid) exclusively bind to nAChR␣7 at nanomolar concentrations (Tocris Bioscience). MLA, in contrast to ␣BGT, discriminates between muscle-and neuronal-type nAChRs. PRP or whole blood samples were pretreated for 30 minutes with antagonists to achieve blockade of the nAChR␣7 channels.
Cell Culture
The properties of the human megakaryoblastic cell line MEG-01 have been described in detail previously. 27 MEG-01 cells were purchased from the German Centre for Biological Material (Braunschweig, Germany) and cultured in RPMI 1640 medium (PAA Laboratories GmbH, Cölbe, Germany) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 100 U/mL penicillin, 100 g/mL streptomycin, and 4 mmol/L L-glutamine at 37°C in a humidified atmosphere of 5% CO 2 . Differentiation of MEG-01 cells to megakaryocyte-like cells was induced by 12-0-tetradecanoylphorbol 13-acetate (TPA) at a concentration of 10 Ϫ8 mol/L. TPA-treated MEG-01 cells (MEG-01/TPA) were monitored for CD41/CD61 expression by flow cytometric analysis and collected after 3 days of cell culture. Cells were harvested for mRNA and protein expression studies.
Real-Time Polymerase Chain Reaction for mRNA Detection and Relative Quantification
Total RNA was extracted from 5ϫ10 6 MEG-01 and MEG-01/TPA cells using a commercial kit (RNeasy Mini Kit; Qiagen, Hilden, Germany). Platelet RNA was obtained from 5ϫ10 8 leukocytedepleted platelets as described in detail previously. 28 cDNA was generated using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany). Real-time polymerase chain reaction (PCR) was performed using specific primers for CHRNA7 (NM_139320: sense, 5Ј-CCAGACTCACTAAATCCTTT-CCA-3Ј; antisense, 5Ј-GAATTGCAGAAAAGCTAAGAGGTT-3Ј) and GAPDH (NM_002046: sense, 5Ј-TCCACTGGCGTCTTCACC-3Ј; antisense, 5Ј-GGCAGAGATGATGACCCTTTT-3Ј) and TaqMan probes from the Universal Probe Library (Roche Applied Science). PCR cycling (ABI 7000, Applied Biosystems, Weiterstadt, Germany) was performed with the following parameters: 10 minutes at 95°C, followed by 40 cycles of 15 s at 95°C and 1 minute at 60°C. Cycle threshold (C t ) values of the GAPDH gene detected under the same PCR conditions served as reference for relative quantification by the following equation (detection limit C t Ͼ40): (C t GAPDH/C t gene)Ϫ(C t GAPDH/40.1).
Protein Expression Analysis
Western blotting was performed according to standard procedures on the total protein extracts (50 g) of leukocyte-depleted platelets of 6 different donors, MEG-01 cells, and MEG-01/TPA cells using a polyclonal anti-nAChR␣7 antibody (clone C-20, Santa Cruz Biotechnology, Heidelberg, Germany). Total cell lysates of mouse brain and human embryonic kidney cells (HEK-293) were applied as positive and negative controls, respectively. Actin was detected as reference protein (clone C-11, Santa Cruz Biotechnology) to compare total protein amounts of the samples loaded on a blot. Surface expression of nAChR␣7 on platelets was measured by using increasing amounts of fluorescein isothiocyanate (FITC)-conjugated ␣BGT (Sigma-Aldrich) in flow cytometry (FACSCalibur, Becton Dickinson, Heidelberg, Germany). For competition studies, nicotine was added before ␣BGT-FITC.
Ca

2؉ Influx in Platelets
For measurement of Ca 2ϩ influx in platelets, PRP of 6 healthy volunteers was treated with 0.5 mol/L prostaglandin I 2 (PGI 2 ) and 0.02 U/mL apyrase for 10 minutes as described elsewhere. 29 PRP was washed and resuspended in Tyrode's buffer (137 mmol/L NaCl, 2.68 mmol/L KCl, 11.9 mmol/L NaHCO 3 , 0.42 mmol/L NaH 2 PO 4 , and 5 mmol/L Hepes at pH 7.4) containing 0.5 mol/L PGI 2 and 10 U/mL heparin at a concentration of 1.5ϫ10 8 platelets/mL. Platelet suspension was loaded with 5 mol/L Fluo-4 in the presence of 2.5 mmol/L probenecid and 10% pluronic acid (Molecular Probes, Invitrogen) for 45 minutes at 37°C. Finally, washed platelets were resuspended at a density of 5ϫ10 5 platelets/L in Tyrode's buffer containing 0.5 mol/L PGI 2 and 2.5 mmol/L probenecid and dispensed in a 96-well plate. Fluorescence signals were recorded continuously for 180 seconds (5 measures per second) using the multilabel plate reader Victor X4 (PerkinElmer, Rodgau, Germany) equipped with 2 injectors. CaCl 2 (2 mmol/L) was added where indicated, and the background fluorescence signal was recorded for 10 seconds before the addition of cholinergic agonists or Tyrode's buffer. The cholinergic agonists ACh (Sigma-Aldrich) and PNU were used at different concentrations as indicated. For investigation of nAChR␣7 channel blockade, Fluo-4 loaded platelets were pretreated for 30 minutes with the cholinergic antagonist ␣BGT (20 nmol/L). At the end of an experiment, the platelets were lysed in the presence of 2 mmol/L Ca 2ϩ by the addition of 0.1% Triton X-100 to obtain the maximum fluorescence signal, and 8 mmol/L EGTA was added for the minimum fluorescence signal. Quantification of the intracellular Ca 2ϩ concentration was performed using the Fluo-4AM kDa of 345 nmol/L as outlined previously. 29 
Analysis of Fibrinogen Receptor Activation and Platelet Degranulation
Binding of Pac-1 antibody (Pac-1, FITC-conjugated monoclonal antibody; BD Bioscience, Heidelberg, Germany) to activated platelets as a marker for active confirmation of surface fibrinogen receptor (GPIIb/IIIa), P-selectin (CD62P, phycoerythrin (PE)-conjugated monoclonal antibody, BD Bioscience) as a marker for the release of ␣-granules, and lysosomal-associated membrane protein 3 (LAMP-3, CD63, R-PE-conjugated) monoclonal antibody; BD Bioscience) as a marker for dense granule secretion was measured in hirudin-coagulated blood by flow cytometry (FACSCalibur). Hirudinized blood samples were used because of the maintained physiological calcium levels. Ten microliters of PRP was added to 100 L of HBS buffer (150 mmol/L NaCl, 5 mmol/L KCL, 1 mmol/L MgSO 4 and 10 mmol/L HEPES, pH 7.4) and incubated in the dark at room temperature for 20 minutes containing 10 L of the desired agonist and saturating concentrations of antibody. To stimulate platelets, the cholinergic agonists CCh and PNU were used alone or in costimulation with the classical platelet agonists ADP and U46619. Compared with platelet aggregometry (see below) the platelet agonists had to be used at higher concentrations (both at 5 mol/L) to achieve significant effects in the flow cytometric studies. According to this, also, CCh was used at higher concentrations (up to 100 mol/L). Where indicated, PRP samples were preincubated with the cholinergic antagonists ␣BGT or MLA (also at higher concentrations: 2 mol/L ␣BGT, 10 mol/L MLA) for 30 minutes at room temperature, followed by incubation with agonists. Cell lysis solution (BD Bioscience) was added, and samples were subjected to flow cytometric analysis. Based on forward and side scatters, a gate was set around the platelet population, and 20 000 events were acquired from each sample. The proportion of active fibrinogen receptor, as well as P-selectin and LAMP3 surface expression, is presented as mean fluorescence intensity.
Whole Blood Platelet Aggregometry
The effect of various nAChR agonists and antagonists on platelet aggregation was investigated by whole blood impedance aggregometry using a multiple platelet function analyzer (Multiplate Instruments, Dynabyte GmbH, Munich, Germany). CCh and PNU were used as cholinergic agonists. Hirudin-anticoagulated blood of 6 healthy, nonsmoking volunteers was either stimulated with cholinergic agonists alone or costimulated with classical platelet agonists U46619 (thromboxane A 2 analog; 0.75 mol/L) and ADP (0.5 mol/L) (Sigma-Aldrich, Tocris Bioscience) according to Multiplate standard protocols. To study the effect of the nAChR␣7-selective antagonists ␣BGT and MLA, blood samples were preincubated with antagonists at nAChR␣7-selective concentrations (␣BGT, 20 nmol/L; MLA, 100 nmol/L) for 30 minutes at room temperature before stimulation with U46619 or ADP. Aggregation was recorded for 6 minutes, and maximum aggregation is given in arbitrary units.
Statistical Analysis
The mean intracellular Ca 2ϩ concentration, flow-cytometric analysis, and aggregation response were determined in PRP and whole blood samples of 6 healthy individuals with or without the given agonists or antagonists. A statistical analysis of the values was performed with t tests for paired samples using SPSS 12.0 (SPSS Inc., Chicago, Ill) statistical software.
Results
Detection of CHRNA7 Gene Transcripts
As a first step toward the identification of nAChR␣7 subunits on platelets, we performed real-time PCR experiments to validate our RNA data of previous microarray analysis. 26, 27 We also included megakaryoblasts (human leukemia megakaryoblastic cell line MEG-01) and in vitro-differentiated megakaryocyte-like cells (TPA-induced MEG-01 cells: MEG-01/TPA). The CHRNA7 gene for nAChR␣7 subunits showed substantial levels of mRNA expression in MEG-01 and MEG-01/TPA cells relative to the level of GAPDH mRNA ( Figure 1A ). Lower but reasonable levels of CHRNA7 gene transcripts were also detected in platelets, confirming our previous results from platelet transcriptome profiling.
Protein Expression of nAChR␣7 Subunits
Western blotting using an anti-nAChR␣7 polyclonal antibody revealed a protein band of the expected size (55 kDa) in the positive control (mouse brain), in all platelet samples, and in MEG-01 and MEG-01/TPA cells ( Figure 1B ). This band was not detected in cell lysates from human embryonic kidney cells (HEK-293), which are devoid of nAChR␣7 subunits. This band was also not detected when using the secondary antibody on its own (data not shown). In addition, we could show significant dose-dependent binding of FITC-conjugated ␣BGT, a nAChR␣7-selective antagonist, to platelets. Competition studies using 500 mol/L nicotine significantly reduced binding of FITC-conjugated ␣BGT to platelets (Figure 1C) . Similar concentrations of ␣BGT were used for the detection of nAChR␣7 expression on endothelial cells. 5 These findings confirmed our RNA data and indicated expression of the nAChR␣7 protein during megakaryopoiesis and in platelets.
nAChR␣7-Mediated Ca 2؉ Entry in Platelets
Cholinergic agonists have been shown to modulate transmembrane transport and intracellular metabolism of Ca 2ϩ in several types of cells. 4 -9 We hypothesized that cholinergic agonists would have similar effects on platelets. As expected, in the presence of extracellular Ca 2ϩ (2 mmol/L), the synthetic nAChR␣7-selective agonist PNU 26 induced Ca 2ϩ entry in platelets (Figure 2A) , whereas in the absence of extracellular Ca 2ϩ , the addition of PNU had no effect on intracellular Ca 2ϩ concentration, confirming that the entry of Ca 2ϩ occurs through the nAChR␣7 channel (Figure 2A ). The rather slow and continuous increase of PNU-induced intracellular Ca 2ϩ could result from the rapid but reversible desensitization states typical of nAChR␣7 channels on nonneuronal cells (see Discussion for other possible reasons). The PNUinduced Ca 2ϩ entry was quantified at 60 seconds after the addition of PNU. This time point was usually the peak value of fluorescence, before intracellular Ca 2ϩ levels decreased, presumably because of the translocation into stores. The PNU-induced Ca 2ϩ entry was significant and concentration dependent in the range of 0.1 to 10 mol/L ( Figure 2B ). The physiological agonist ACh (1 to 100 mol/L) also induced concentration-dependent Ca 2ϩ entry in platelets (data not shown). Furthermore, in the presence of the selective and competitive nAChR␣7 antagonist ␣BGT (20 nmol/L) the PNU-induced Ca 2ϩ entry was completely blocked (Figure 2A  and 2C) . ␣BGT also blocked basal Ca 2ϩ entry in platelets to some extent, but this did not reach significance ( Figure 2C ). These results indicate that nAChR␣7 subunits form functional ion channels that contribute to transmembrane Ca 2ϩ entry in platelets.
Effect of Cholinergic Agonists and Antagonists on Platelet Activation
To investigate the impact of nAChR␣7 channels on platelet function in terms of fibrinogen receptor activation and platelet degranulation, we measured expression of the corresponding surface molecules GPIIb/IIIa, CD62P, and CD63 by flow cytometry. The stable ACh analog CCh (1 to 100 mol/L) and the nAChR␣7-selective agonist PNU (0.1 to 10 mol/L) had no significant effect on resting platelet activation and platelet degranulation (data not shown). The synergistic action of CCh and PNU was tested in costimulation experiments with classical platelet agonists as shown for other neurotransmitters. [15] [16] [17] [18] Platelets were costimulated with 5 mol/L ADP or 5 mol/L U46619 in addition to CCh (1 to 100 mol/L) or PNU (0.1 to 10 mol/L). CCh and PNU had no significant effect on ADP-or U46619-induced platelet degranulation measured by CD62P and CD63 surface expression (data not shown). However, both cholinergic agonists showed a significant increase of ADP-and U46619-induced fibrinogen receptor activation, as measured by Pac-1 antibody binding (Figure 3) . Furthermore, platelet samples were pretreated with the nAChR␣7-selective antagonists ␣BGT (2 mol/L) and MLA (10 mol/L) before stimulation. CChand PNU-induced increase in ADP-or U46619-mediated Pac-1 binding was completely abolished in the presence of the nAChR␣7 antagonists (Figure 3 ). Taken together, the inhibitory effects of nAChR␣7 antagonists observed using U46619 as platelet agonist were stronger compared with the experiments with ADP stimulation. This could be due to the fact that U46619 stimulation primarily causes intracellular Ca 2ϩ mobilization independent of granule secretion. 30 In summary, our data suggest that nAChR␣7 channels are involved in fibrinogen receptor activation but not in platelet degranulation.
Effect of Cholinergic Agonists and Antagonists on Platelet Aggregation
Platelet activation and the subsequent upregulation of fibrinogen receptors results in fibrinogen-mediated platelet aggregation. Because cholinergic agonists increased fibrinogen receptor activation, we were also interested in the potential role of the nAChR␣7 channels in platelet aggregation. We applied impedance aggregometry in hirudinized whole blood and tested the effect of cholinergic agonists on platelet aggregation. As expected, the cholinergic agonist CCh (0.1 mol/L to 1 mmol/L) and the nAChR␣7-selective agonist PNU (0.1 to 10 mol/L) applied alone had no effect on platelet aggregation (data not shown). We also investigated potential synergistic effects of cholinergic and classical platelet agonists (ADP and U46619). , neither PNU nor ␣BGT had an effect on intracellular Ca 2ϩ levels in platelets.
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However, none of the cholinergic agonists enhanced platelet aggregation in costimulation with ADP (0.5 mol/L) or U46619 (0.75 mol/L) (Figure 4 ). In addition, we examined the effect of cholinergic antagonists to block the nAChR␣7 channels before platelet stimulation. The nAChR␣7-selective antagonists ␣BGT (20 nmol/L) and MLA (100 nmol/L) were used to pretreat hirudinized blood samples before stimulation of platelets using classical agonists (Figure 4 ). Both antagonists significantly inhibited ADP-and U46619-induced platelet aggregation. These results clearly indicate that blockade of the nAChR␣7 channels cause impaired platelet function. 
Discussion
We describe for the first time a functional cholinergic receptor, ie, the nAChR␣7 Ca 2ϩ channel, in human platelets. The nAChR␣7 subunits are also expressed in cells of the megakaryocytic lineage. We found clear evidence that agonist binding to platelet nAChR␣7 receptors elicits Ca 2ϩ influx and enhances fibrinogen receptor activation. Blockade of the nAChR␣7-mediated Ca 2ϩ influx significantly impaired platelet function in vitro. According to our observations, cholinergic signaling seems to be involved in fibrinogen receptor activation but not in platelet degranulation. This could indicate a role of nAChR␣7 channels in early aggregatory events. Because calcium is required for the fibrinogen receptor to undergo conformational transition, 31 we propose that nAChR␣7 channels contribute to that pathway.
The question arises, what could be the impact of nAChR␣7-mediated Ca 2ϩ entry with regard to platelet function in vivo? Platelets are known to store an impressive pool of neurotransmitters in their dense granules, which are released during activation and cause positive feedback activation. [15] [16] [17] [18] Because platelets have been proposed to contain ACh, 1 we suggest that on activation, platelets release stored ACh, which stimulates nAChR␣7 channels in an autocrine mechanisms. A similar mechanism was reported for the neurotransmitter glutamate, which is stored in platelet-dense granules and is released on activation. 17 Glutamate promotes platelet activation through binding to glutamate channels on the platelet surface. On the other hand, other cells in close contact with platelets (eg, endothelial cells or mononuclear cells) could also represent a source and target for ACh, 1 so a paracrine mechanism could also apply. Further evidence for the autocrine cholinergic mechanism was provided by our observation that the nAChR␣7 antagonist ␣BGT lowered the basal Ca 2ϩ entry without exogenously added cholinergic agonist. This could indicate that during platelet preparation, endogenous ACh is released, which continuously stimulates nAChR␣7 channels. A similar phenomenon of inhibition of basal Ca 2ϩ entry has been described previously in keratinocytes. 32 We measured the contribution of nAChR␣7 channels to the Ca 2ϩ entry into platelets in the nanomolar range (50 to 100 nmol/L). At much higher concentrations (mmol/L) of cholinergic agonists, we could observe even higher Ca 2ϩ responses (data not shown). However, we focused on using physiologically relevant or nAChR␣7-selective concentrations of agonists and antagonists because the use of higher concentrations would bury a high risk of unspecific nonreceptor properties, such as the interaction with lipid membranes. The rather small Ca 2ϩ entry induced by nAChR␣7-selective agonist concentration is very similar to the Ca 2ϩ entry reported for the ATP-gated P2X 1 channel that is a very rapidly desensitizing ion channel. 33 In contrast to the short peak of Ca 2ϩ entry typically observed for the P2X 1 channels, we found a rather slow and continuous increase of intracellular Ca 2ϩ for the nAChR␣7 channels, with a maximum approximately 1 minute after addition of the agonist. Although this does not reflect the typical behavior of neuronal nAChR␣7 channels, it appears to be characteristic for nonneuronal nAChR. In epithelial cells and in keratinocytes, similar observations were made showing a rather long-lasting nicotine-induced Ca 2ϩ influx with a peak after 2 minutes. 34 -36 This could result from the rapid but reversible desensitization states typical of nAChR␣7 channels. 37 On the other hand, the signaling mechanisms through nAChR␣7 channels in nonexcitable cells are diverse, as reviewed by Sharma and Vijayaraghavan. 3 Ca 2ϩ influx on nAChR␣7 channels can be accompanied by acquisition of Ca 2ϩ from internal stores and Ca 2ϩ influx through voltage-gated channels. Because voltage-gated channels are not identified on platelets so far, the participation of these channels seems unlikely. However, contribution of the Ca 2ϩ induced release of Ca 2ϩ from intracellular stores could add to the prolonged Ca 2ϩ response observed in our experiments. Furthermore, the continuous presence of a cholinergic agonist (endogenous ACh) might cause a permanent switch between the open and closed state, and the cumulative Ca 2ϩ influx of all nAChR␣7 channels is observed.
Interestingly, the components of the nonneuronal cholinergic system are expressed very early during fetal hematopoiesis, and nicotine affects colonization of the fetal bone with hematopoietic stem/progenitor cells. 38 In an older report, cholinergic signaling during early megakaryopoiesis was described. 39 In our study, we found expression of the nAChR␣7 subunits in cells of the megakaryocytic lineage. This could be part of a functional cholinergic system involved in the regulation of megakaryopoiesis and thrombopoiesis. In preliminary in vitro experiments, we observed inhibition of megakaryopoietic differentiation in the presence of cholinergic substances. Such observations fit to the models of "nervous hematopoiesis" with bone marrow stem and precursor cells under direct and indirect control of the nervous system. 40 Platelet activation in thrombosis and hemostasis is supported through positive feedback mechanisms mediated by the release of secondary mediators from activated platelets and neighboring vascular cells. In recent years, more and more studies have emerged in which neurotransmitters are suggested to cause positive feedback on their corresponding platelet receptors. On the basis of our findings, we add the cholinergic system as a new pathway that supports platelet function through Ca 2ϩ -mediated mechanisms. Further exploitation of the contribution of nAChRs to megakaryopoiesis, thrombosis, and hemostasis could lead to the discovery of new cholinergic drugs as alternative platelet therapies.
